Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Haimin Chen, Haiqi Chen, Yan Zhou, Weiwei Xu, Jingjing Yu, Yao Xu & Fan Zhou. (2023) Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis. Hematology 28:1.
Read now
Read now
Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf & Saad Z. Usmani. (2021) A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Review of Hematology 14:12, pages 1049-1058.
Read now
Read now
Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou & Evangelos Terpos. (2020) Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection. OncoTargets and Therapy 13, pages 6405-6416.
Read now
Read now
Articles from other publishers (37)
Monique Hartley-Brown & Ateh Zinkeng. (2023) Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line. Hematology 2023:1, pages 443-449.
Crossref
Crossref
Guoyuan Tang, Shan Huang, Ji Luo, Yingmiao Wu, Shuai Zheng, Rongsheng Tong, Ling Zhong & Jianyou Shi. (2023) Advances in research on potential inhibitors of multiple myeloma. European Journal of Medicinal Chemistry 262, pages 115875.
Crossref
Crossref
Jing Qi, Jinhui Xu, Hwee Ting Ang, Bingbing Wang, Nipun Kumar Gupta, Srinivas Reddy Dubbaka, Patrick O’Neill, Xianwen Mao, Yanwei Lum & Jie Wu. (2023) Electrophotochemical Synthesis Facilitated Trifluoromethylation of Arenes Using Trifluoroacetic Acid. Journal of the American Chemical Society.
Crossref
Crossref
Yu Feng, Jingcao Huang, Fangfang Wang, Zhimei Lin, Hongmei Luo, Qian Li, Xin Wang, Xiang Liu, Xinyu Zhai, Qianwen Gao, Lingfeng Li, Yue Zhang, Jingjing Wen, Li Zhang, Ting Niu & Yuhuan Zheng. (2023) Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma. Life Sciences 333, pages 122157.
Crossref
Crossref
Efstathios Kastritis, Maria Gavriatopoulou, Eirini Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Nikoleta Kokkali, Evangelos Eleutherakis-Papaiakovou, Rodanthi Syrigou, Despina Fotiou, Evangelos Terpos & Meletios A. Dimopoulos. (2023) Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes. Clinical Lymphoma Myeloma and Leukemia 23:11, pages 844-849.
Crossref
Crossref
Fan-Fan Shang, Qing Lu, Tailiang Lin, Miaoxia Pu, Ruoxuan Xiao, Wanmei Liu, Hao Deng, Hongyan Guo, Zhe-Shan Quan, Chunyong Ding & Qing-Kun Shen. (2023) Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry.
Crossref
Crossref
Stella Newell, Pauline J. van der Watt & Virna D. Leaner. (2023) Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy. IUBMB Life.
Crossref
Crossref
Jennifer R Landes, Brooke R Bartley, Stephen A Moore, Qin He, Rebecca Simonette, Peter L Rady, Hung Q Doan & Stephen K Tyring. (2023) Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines. Clinical and Experimental Dermatology 48:8, pages 903-908.
Crossref
Crossref
Chang‐Bin Jing, Nicole Prutsch, Shuning He, Mark W. Zimmerman, Yosef Landesman & A. Thomas Look. (2023)
Synthetic lethal targeting of
TET2
‐mutant haematopoietic stem and progenitor cells by
XPO1
inhibitors
. British Journal of Haematology 201:3, pages 489-501.
Crossref
Crossref
Jennifer R. Landes, Stephen A. Moore, Brooke R. Bartley, Hung Q. Doan, Peter L. Rady & Stephen K. Tyring. (2022) The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. Journal of Cancer Research and Clinical Oncology 149:5, pages 2139-2155.
Crossref
Crossref
Zengbin Wang, Banglun Pan, Yuxin Yao, Jiacheng Qiu, Xiaoxia Zhang, Xiaoxuan Wu & Nanhong Tang. (2023) XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 160, pages 114402.
Crossref
Crossref
Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Veena Vijayan, Deepak Kumar, Jashwanth Naik, Suresh Thareja, Jagat Pal Yadav, Prateek Pathak, Maria Grishina, Amita Verma, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas & Pradeep Kumar. (2023) Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals 16:2, pages 299.
Crossref
Crossref
Leila Ouni & Ali Ramazani. (2023) In Silico Screening of Some Anti-Cancer Drugs Against the Main Protease
of COVID-19 Using Molecular Docking. Letters in Organic Chemistry 20:1, pages 77-90.
Crossref
Crossref
Elham Roshandel, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Saeid Abroun, Reza Mirfakhraie & Abbas Hajifathali. (2023) NK cell therapy in relapsed refractory multiple myeloma. Clinical Immunology 246, pages 109168.
Crossref
Crossref
Michele Bibas. 2023. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Aathira Sujathan Nair, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim & Bijo Mathew. (2022) FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years. Processes 10:10, pages 2054.
Crossref
Crossref
Fang Hu, Xiao-Qin Chen, Xue-Ping Li, Yu-Xiu Lu, Si-Liang Chen, Da-Wei Wang, Yang Liang & Yu-Jun Dai. (2022) Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma. International Immunopharmacology 108, pages 108722.
Crossref
Crossref
Hanxi Yu, Shuangshuang Wu, Shuang Liu, Xinyu Li, Yuqing Gai, Hai Lin, Yue Wang, Holly Edwards, Yubin Ge & Guan Wang. (2022) Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine 26:9, pages 2646-2657.
Crossref
Crossref
Boaz Nachmias, Dilshad H. Khan, Veronique Voisin, Arvind S. Mer, Geethu Emily Thomas, Nadav Segev, Jonathan St-Germain, Rose Hurren, Marcela Gronda, Aaron Botham, Xiaoming Wang, Neil Maclean, Ayesh K. Seneviratne, Nathan Duong, Changjiang Xu, Andrea Arruda, Elias Orouji, Arash Algouneh, Razqallah Hakem, Liran Shlush, Mark D. Minden, Brian Raught, Gary D. Bader & Aaron D. Schimmer. (2022) IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells. Leukemia 36:5, pages 1283-1295.
Crossref
Crossref
Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nermeen N. Welson, Gaber El-Saber Batiha & Carlos Adam Conte-Junior. (2022) Selinexor and COVID-19: The Neglected Warden. Frontiers in Pharmacology 13.
Crossref
Crossref
Zhi Zong, Yujun Wei, Jiang Ren, Long Zhang & Fangfang Zhou. (2021) The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer 20:1.
Crossref
Crossref
Song Liu, Wenliang Qiao, Qingxiang Sun & Youfu Luo. (2021) Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor. Journal of Medicinal Chemistry 64:21, pages 15534-15548.
Crossref
Crossref
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Feng Wang, Cosmina Hogea, Shannon Allen Ferrante, Boris Gorsh, Jenny Willson & Venediktos Kapetanakis. (2021) DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma. Advances in Therapy 38:11, pages 5501-5518.
Crossref
Crossref
Klaus Podar & Xavier Leleu. (2021) Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers 13:20, pages 5154.
Crossref
Crossref
Guoqiang Sun, Dawei Rong, Zhouxiao Li, Guangshun Sun, Fan Wu, Xiao Li, Hongyong Cao, Ye Cheng, Weiwei Tang & Yangbai Sun. (2021) Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Audrey N Jajosky, Nathaniel P Havens, Navid Sadri, Kwadwo A OduroJrJr, Erika M Moore, Rose C Beck & Howard J Meyerson. (2021) Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders. American Journal of Clinical Pathology 156:3, pages 433-444.
Crossref
Crossref
Rajiv Pathak, Francesca Zin, Christian Thomas, Susanne Bens, Tenzin Gayden, Jason Karamchandani, Roy W. Dudley, Karolina Nemes, Pascal D. Johann, Florian Oyen, Uwe Kordes, Nada Jabado, Reiner Siebert, Werner Paulus, Marcel Kool, Michael C. Frühwald, Steffen Albrecht, Ganjam V. Kalpana & Martin Hasselblatt. (2021) Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathologica 142:2, pages 361-374.
Crossref
Crossref
Ota Fuchs. 2021. Multiple Myeloma. Multiple Myeloma.
Asfar S. Azmi, Mohammed H. Uddin & Ramzi M. Mohammad. (2020) The nuclear export protein XPO1 — from biology to targeted therapy. Nature Reviews Clinical Oncology 18:3, pages 152-169.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Jinsha Liu, Priyanka Pandya & Sepideh Afshar. (2021) Therapeutic Advances in Oncology. International Journal of Molecular Sciences 22:4, pages 2008.
Crossref
Crossref
Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan & Thomas Delea. (2021) Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer Journal 11:2.
Crossref
Crossref
Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath & Ivan Urits. (2021) Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Current Oncology 28:1, pages 640-660.
Crossref
Crossref
Hila Magen, Mika Geva, Yulia Volchik, Abraham Avigdor & Arnon Nagler. (2020) Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. Clinical Lymphoma Myeloma and Leukemia 20:12, pages e947-e955.
Crossref
Crossref
Slavisa Ninkovic & Hang Quach. (2020) Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. Cancers 12:11, pages 3488.
Crossref
Crossref
Rami A. Al-Horani & Srabani Kar. (2020) Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses 12:10, pages 1092.
Crossref
Crossref
Ashish Kothari, Vanya Singh, Uttam Kumar Nath, Sandeep Kumar, Vineeta Rai, Karanvir Kaushal, Balram Ji Omar, Atul Pandey & Neeraj Jain. (2020) Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?. Biology 9:9, pages 243.
Crossref
Crossref